SeaSpine Holdings (SPNE) Commences Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
SeaSpine Commences Public Offering of Common Stock
January 7, 2020 4:03 PM ESTCARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE) (SeaSpine or the Company), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by SeaSpine.
Piper Sandler & Co. and Canaccord Genuity LLC are acting as joint book-running managers, SunTrust Robinson Humphrey, Inc. is acting as lead manager and BTIG, LLC and Ladenburg Thalmann & Co. Inc. are acting as co-managers for the... More
SeaSpine Announces Preliminary Results for Fourth Quarter and Full-Year 2019; Reports Record Revenue, Driven by Greater Than 20% U.S. Spinal Implants Growth
January 7, 2020 4:00 PM ESTCARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today preliminary financial results for the fourth quarter and full-year 2019, with U.S Spinal Implants revenues expected to reflect growth within the 20% to 21% range.Â
We are pleased by our overall strong revenue performance in the fourth quarter and, in particular, the growth in excess of 20% in the U.S. Spinal Implants portfolio, said Keith Valentine, President and Chief Executive Officer. Based on the rapid... More



